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as a novel target of PI3Kγ in the MDA-MB-231
metastatic breast cancer cell line
Meizhi Niu1†, Manuela Klingler-Hoffmann1†, Julie A Brazzatti1,3, Briony Forbes1, Chareeporn Akekawatchai1,2,
Peter Hoffmann1 and Shaun R McColl1*Abstract
Background: Cancer cell migration is fundamentally required for breast tumour invasion and metastasis. The
insulin-like growth factor 1 tyrosine kinase receptor (IGF-1R) and the chemokine G-protein coupled receptor, CXCR4
have been shown to play an important role in breast cancer metastasis. Our previous study has shown that IGF-1R
can transactivate CXCR4 via a physical association in the human MDA-MB-231 metastatic breast cancer cell line and
that this plays a key role in IGF-I-induced migration of these cells. In the present study we used pharmacological
inhibition and RNAi to identify PI3Kγ as an important migration signalling molecule downstream of receptor
transactivation in MDA-MB-231 cells. To identify PI3Kγ-regulated proteins upon transactivation of CXCR4 by IGF-I, we
undertook a comparative proteomics approach using 2-D- Fluorescence Difference Gel Electrophoresis (DIGE) and
identified the proteins by mass spectrometry.
Results: These experiments identified eukaryotic elongation factor 2 (eEF2) as a novel downstream target of PI3Kγ
after activation of the IGF-1R-CXCR4 heterodimer by IGF-I. Further analysis demonstrated that eEF2 is
phosphorylated in MDA-MB-231 cells in response to IGF-I and that this is dependent on PI3Kγ activity.
Conclusions: Our data imply a novel role for PI3Kγ in facilitating cell migration by regulating phosphorylation of eEF2.
Keywords: Receptor transactivation, Cell migration, IGF-I, CXCR4, PI3Kγ, eEF2, 2D-DIGEBackground
Breast cancer metastasis is a multi-step process regu-
lated by a number of homeostatic factors including che-
mokines and growth factors through interaction with
their corresponding receptors, G protein-coupled recep-
tors (GPCRs) and tyrosine kinase receptors (RTKs) re-
spectively. A number of studies have shown that the
signaling pathways initiated by these receptors are not
activated in a linear way and instead involve activation
of interacting signaling networks. For instance, in blad-
der cancer cells, it has been shown that LPA promotes
cell migration and invasion via phosphorylation of EGFR* Correspondence: shaun.mccoll@adelaide.edu.au
†Equal contributors
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reproduction in any medium, provided the orand subsequent activation of mitogen-activated protein
kinase (MAPK) signalling [1]. Recent evidence indicates
an additional level of complexity in these systems: recep-
tor heterodimerization whereby transactivation between
two distinct receptors occurs [2]. Our previous data have
demonstrated that insulin-like growth factor 1 receptor
(IGF-1R) can transactivate the chemokine receptor
CXCR4 via a physical association between IGF-1R and
CXCR4 in human MDA-MB-231 metastatic breast can-
cer cells and that this plays a key role in IGF-I-induced
motility of these cells [2]. Furthermore, RNAi-mediated
knockdown of CXCR4 in these cells prevents experi-
mental metastasis [3]. Therefore cancer metastasis
appears to depend on CXCR4 and the signalling occur-
ring downstream of this receptor. However, the down-
stream signaling events occurring as a result of this
transactivation are yet to be elucidated.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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strated to be critical in cell migration downstream of
both GPCRs [4] and RTKs [5,6]. PI3Ks are grouped into
three classes according to sequence homology, substrate
preference and tissue distribution [7]. The most exten-
sively investigated PI3Ks, class I PI3Ks are further
divided into class IA and class IB. Class IA PI3Ks, in-
cluding PI3Kα, PI3Kβ and PI3Kδ are mainly activated by
RTKs while the class IB PI3K, known as PI3Kγ is acti-
vated by GPCRs [8] although PI3Kδ has also been
shown to be activated downstream of GPCRs notably,
CXCR4 [9]. Class I PI3Ks phosphorylate the 3’-OH
group on phosphatidylinositols in the plasma membrane,
leading to the recruitment and activation of adaptor and
effector proteins containing a pleckstrin homology (PH)
domain. This triggers a series of downstream signaling
cascades to regulate survival, metabolism, growth and
migration [10], which can be inhibited by treatment with
the well-characterized pan-PI3K inhibitors wortmannin
[11] and LY294002 [12]. Furthermore, a number of re-
cent studies have demonstrated distinct roles of specific
PI3K isoforms in response to GPCR and RTK activation
in a variety of cancer cell lines, including breast cancer
cells,using isoform-specific inhibitors. For instance, it
has been shown that PI3Kδ is the most important class
IA PI3K in the regulation of EGF-driven motility of
breast cancer cells, whereas PI3Kβ is required for direc-
ted migration but PI3Kα does not appear to play a role
in breast cancer cell migration [13]. With respect to the
class IB PI3K, it has been demonstrated that PI3Kγ reg-
ulates LPA-induced Akt activity and cell proliferation in
pancreatic cancer cells [14] and also plays an important
role in cell invasion and adhesion of melanoma cells in
response to CXCL12 [15]. However, the role of specific
PI3K isoforms in receptor transactivation has not been
investigated.
To elucidate the underlying mechanism by which IGF-
1R-CXCR4 transactivation regulates cell migration, we
investigated signaling transduction pathways activated
downstream of IGF-I-induced activation of IGF-1R-
CXCR4 heterodimers in invasive MDA-MB-231 cells, fo-
cusing particularly on the role of PI3Ks and subsequent
downstream effectors. The experimental design for this
study is outlined in Additional file 1: Figure S1. Our
results show that PI3Kγ is the major class I PI3K iso-
form regulating cell migration in response to ligation of
IGF-1R-CXCR4 heterodimers by IGF-I in MDA-MB-231
cells.After we had established the central role of PI3Kγ
in regulation of migration downstream of transactiva-
tion, we wanted to identify downstream effectors of
PI3Kγ. We identified eukaryotic elongation factor 2 (eEF2)
as one of the downstream targets that are dependent on
PI3Kγ activation using 2D Fluorescence Difference Gel
Electrophoresis (DIGE) and mass spectrometry analysis.Phosphorylation of eEF2 on Thr56 decreases it affinity to
the ribosome, thereby inhibiting elongation, a key step in
the process of translating mRNA. Recently, it has been
shown, that phosphorylation of eEF2 facilitates inhibition
of protein synthesis downstream of DNA damage [16].
Thus, our findings imply that PI3Kγ facilitates breast can-
cer cell migration through a novel mechanism by deacti-
vating eEF2, thereby inhibiting protein synthesis after IGF-
1R-CXCR4 transactivation.Results
Phosphorylation of Akt is dependent on CXCR4
Our previous results have shown that migration of MDA-
MB-231 is dependent on CXCR4 expression, because
knock-down of CXCR4 led to reduced migration upon
IGF-I stimulation [17]. Therefore, we determined if activa-
tion of PI3K occurs downstream of CXCR4 following
stimulation of the cells with IGF-I. To achieve this, we
used the phosphorylation of Akt on S473 as a readout for
PI3K activity. Knock-down of CXCR4 nearly completely
abrogated the phosphorylation of Akt in MDA-MB-231
cells upon stimulation with IGF-I (Figure 1A and B).Treatment with the selective PI3Kγ inhibitor suppresses
IGF-I-induced migration
The two major PI3K indicated downstream of G-protein
coupled receptors are PI3Kγand PI3Kδ. Both are expressed
in MDA-MB-231 cells as determined by Western-Blot
analysis (data not shown). To determine if PI3Kγ or PI3Kδ
play a role in IGF-I-induced migration of MDA-MB-231
cells, the cells were pre-treated with specific inhibitors, as
described previously [18] and cell migration in response to
IGF-I was determined using a modified Boyden chamber
assay. The inhibition efficiency of the selective PI3Kδ in-
hibitor IC87114 was first examined. MDA-MB-231 cells
migrated towards IGF-I in a dose-dependent manner and
this was only slightly inhibited when cells were pretreated
with 10 μM IC87114 (Figure 1C). In contrast migration
was completely abrogated after preincubation with 10 μM
AS605240, the selective PI3Kγ inhibitor (Figure 1D).
Lower levels of inhibitor treatment (2 μMAS605240) also
led to a significant inhibition in migration upon stimula-
tion with 100 nM IGF-I. This involvement of PI3Kγ in
IGF-I-induced cell migration was dependent on CXCR4
transactivation as AS605240 had no effect on IGF-I-
induced MDA-MB-231 cell migration in CXCR4 knock-
down cells (data not shown). Moreover, AS605240 treat-
ment had no effect on IGF-I-induced migration of MCF-7
cells, which do not express a functional IGF-1R-CXCR4
heterodimer [2] (data not shown). We conclude that PI3Kγ
most likely regulates migration in MDA-MB-231 cells
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Figure 1 PI3Kγ plays a key role in IGF-I-induced migration of MDA-MB-231 cells. (A) MDA-MB-231 cells or MDA-MB-231 CXCR4 knock-down
cells were treated with 0.1 nM IGF-I and Akt phosphorylation was assessed. (B) Akt phosphorylation was quantified by densitometry, normalized
to β-actin and expressed as a value relative to the 10-minute control values. (C) MDA-MB-231 cells were treated with DMSO (diluent control) or
10 μM IC87114 for 1 hour and chemotaxis in response to IGF-I assessed. (D) MDA-MB-231 cells were treated with diluent or 2 μM AS605240 for 1
hour and chemotaxis in response to IGF-I assessed. * - significantly different from the control values at, p<0.05 (E) MDA-MB-231 cells were
incubated in serum-free medium for 1 hour and stimulated with 0.1 nM IGF-I for 5 min. Cell membrane fractions were analyzed by SDS-PAGE and
Western blot using anti-p110γ antibody. The Western-blots were stripped and reprobed with anti-pan-cadherin antibodies as a loading control.
(F) Membrane translocation of p110γ was quantified by densitometry analysis of three independent experiments. * - significantly different from
the control values at, p<0.05 (G) MDA-MB-231 cells were either treated with diluent or 2 μM AS605240 for 1 hour and Akt phosphorylation was
assessed. (H) Akt phosphorylation was quantified by densitometry, normalized to β-actin and expressed as a value relative to the 10-minute
control-treated values. * - significantly different from the control values (2-way ANOVA with Bonferroni post-test) at ***, p<0.001. Unless
otherwise stated, data are expressed as mean ± sem from at least three experiments.
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membrane after IGF- stimulation
To provide further evidence that IGF-I activates PI3Kγ
in MDA-MB-231 cells, the translocation of the p110γ to
the membrane was investigated [19]. MDA-MB-231 cells
were incubated with IGF-I for 5 minutes and membrane
fractions were compared for the presence of p110γ by
Western blot analysis (Figure 1E). Three independent
experiments were analysed by densitometry (Figure 1F).
The results of these experiments clearly indicate that
IGF-I induces translocation of p110γ to the membrane.
Treatment with the selective PI3Kγ inhibitor suppresses
phosphorylation of Akt
One of the earliest detectable events downstream of
PI3K is phosphorylation of Akt/PKB [20]. In fact, Akt
phosphorylation on S473 is commonly used as surrogate
readout of PI3K activation. Therefore, Akt phosphoryl-
ation upon IGF-1R-CXCR4 transactivation in response
to IGF-I was investigated by Western blot analysis using
phospho-Akt antibody. Cells, either untreated or treated
with 2 μM of AS605240 were stimulated with IGF-I and
the lysates were immunoblotted with phospho-Akt antibody.
The levels of phospho-Akt were significantly decreased
after AS605240 treatment (Figure 1G). Three independent
experiments were analysed by densitometry (Figure 1H). InC
n.s.
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p-Akt (S473)






Figure 2 Knock-down of p110γ inhibits cell migration and phosphory
MB-231 cells in which p110γ had been knocked down by RNAi, or control
in culture for 5 days, or growth in soft agar for 2 weeks. (B) Control and p1
various concentrations of IGF-I. All panels are expressed as the mean ± SEM
triplicate. Asterisks indicate significantly different from the control values (S
of MDA-MB-231 cells or p110γ knock-down cells was assessed in response
representative of at least 3 independent experiments conducted with simil
normalized to the level of β-actin and expressed as a value relative to the
experiments) as described in Materials and Methods. Asterisks indicate sign
Bonferroni post-test) at ***, p<0.001.summary, these data indicate that PI3Kγ is the major iso-
form regulating phosphorylation of Akt and migration
downstream of IGFR-CXCR4 transactivation.
Effect of p110γ knock-down on IGF-I-induced
transactivation of CXCR4
To further investigate the role of PI3Kγ in IGF-I-
induced transactivation of CXCR4, p110γ was knocked
down in MDA-MB-231 cells as previously reported [17].
RNAi-mediated knockdown of p110γwas achieved to ap-
proximately 85% and had no effect in cell proliferation
or growth in soft-agar assays (Figure 2A). Thus, the effect
of knockdown of p110γ on IGF-I-induced MDA-MB-231
cell migration and Akt phosphorylation was examined.
Both migration of MDA-MB-231 cells (Figure 2B) and
phosphorylation of Akt (Figures 2C & D) in response to
IGF-I were significantly inhibited by knockdown of p110γ
(Figure 2B). Taken together, these results confirm that
PI3Kγ is required for IGF-I-induced migration of MDA-
MB-231 cells, and this is dependent on transactivation of
CXCR4 by IGF-1R.
Proteomic analysis
To identify novel substrates of PI3Kγ that play a role in
MDA-MB-231 cell migration upon IGF-I-induced IGF-1R-
CXCR4 transactivation, a 2D DIGE proteomic approachlation of Akt in MDA-MB-231 cells after IGF stimulation. (A) MDA-
knockdown cell (expressing scrambled RNAi) were assessed for growth
10γ knockdown cells were tested for their chemotactic response to
from at least three separate experiments, each performed in
tudent’s unpaired t test) at *, p<0.05. (C) Akt phosphorylation on S473
to 0.1 nM IGF-I at the time points indicated. These data are
ar results. (D) Akt phosphorylation was quantified by densitometry,
10 minute control-treated values (mean ± SEM of three independent
ificantly different from the control values (2-way ANOVA with
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PI3Kγ, with a particular focus on phosphorylation, control
and PI3Kγ knockdown cells were treated with or without
IGF-I for 5 minutes, a time point at which PI3Kγ is max-
imally active in this system (as shown by phosphorylation
of Akt as a readout for PI3Kγ activity), and the cytosolic
fraction was collected. For each tested condition, triplicate
biological replicates were obtained and reverse-labeled with
Cy3 or Cy5 while the Cy2 dye was used for the internal
standard control for normalisation and quantitation of the
Cy3- and Cy5-labeled samples. The samples were com-
bined and resolved on 2D gel electrophoresis and proteins
were analysed using DeCyder 2D software. According to
the Decyder software analysis, about 427 protein spots
were visualized, 10 of which exhibited differences in pro-
tein abundance between the control and p110γ knockdown
cells under resting conditions (Figure 3A+B). The prote-
omic analysis after IGF-I stimulation showed that about
1207 protein spots in the one 2D-gel were detected, 38 of
which exhibited alterations in protein abundance in the
absence of p110γ (Figure 3C+D). Protein abundance






Figure 3 Representative overlay 2D gels images of MDA-MB-231 cells
proteome of MDA-MB-231 cells and p110γ knockdown cells without stimu
or Cy5 while the pool of these six samples was labeled with Cy2 as the int
subjected to 2D gel separation, followed by scanning at 100 μm resolution
similar results. (B) Cy5-labeled representative gel of the protein fractions fro
protein spots with altered abundance. (C) Overlay gel image of the cytosol
min stimulation with IGF-1. Cytosolic fractions from triplicate samples were
labeled with Cy2 as the internal pooled standard. These labeled samples w
scanning at 100 μm resolution using a Typhoon Trio. These data are repres
the area containing the spots 101, 102 and 106. (D) Cy5-labeled representa
labeled rectangles indicate the protein spots with altered abundance.Student’s t-test p-value of less than 0.05. For identified
abundance changes, fold-changes between the control and
p110γ knockdown cells without and with IGF stimulation
are listed in Tables 1 and 2.
LC-ESI-MS/MS was applied to identify the differentially-
expressed proteins between the control and p110γ knock-
down cells. The Mascot search results are detailed in
Tables 1 and 2 for each identification. Two of the proteins
identified by MS were regulated by p110γ under both IGF-
I and non-IGF-I stimulation conditions: Pyruvate kinase
isozyme M1/M2 (KPYM) and Phosphoglycerate Kinase 1
(PGK1). Four of the proteins identified were regulated by
p110γ exclusively after IGF-I stimulation: Alpha-enolase
(ENOA), L-lactate dehydrogenase A chain (LDHA), Purine
nucleoside phosphorylase (PNPH) and eukaryotic elong-
ation factor 2 (eEF2). All other differentially-regulated
spots were identified as BSA or keratin,which were most
likely added through unavoidable contamination. Three of
the identified proteins are involved in metabolism, while
eEF2 is known as a regulator of protein synthesis. Because
of the previous implication of other PI3Ks in eEF2 activity












and p110γ KD cells. (A) Overlay gel image of the cytosolic
lation. Cytosolic fractions from triplicate samples were labeled with Cy3
ernal pooled standard. These labeled samples were combined and
using a Typhoon Trio. These data are representative of 3 gels run with
m p110γ knockdown cells. Number-labeled rectangles indicate the
ic proteome of MDA-MB-231 cells and p110γ knockdown cells after 5
labeled with Cy3 or Cy5 while the pool of these six samples was
ere combined and subjected to 2D gel separation, followed by
entative of 3 gels run with similar results. The white rectangle indicates
tive gel of the protein fractions from p110γ knockdown cells. Number-
Table 1 List of differentially-expressed proteins between control and p110γ knockdown cells without IGF-I stimulation
determined by DIGE and identified by MSa









KPYM_HUMAN 58.5/7.96 122 1.2 62/566 49 1121
Phosphoglycerate
kinase 1
PGK1_HUMAN 45.0/8.30 222 1.5 39/540 44 607
aAll other differentially-regulated spots were identified as BSA or keratin.
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tensity profiles of a representative spot 101 identified as
eEF2 is shown in Figure 4A. All biological replicates
showed a similar increase in abundance (Figure 4B). The
characteristics of the abundance of this protein as well as
the short stimulation time used in the experiment strongly
suggest that the difference observed is due to a posttransla-
tional modification, and based on the shift from the acidic
to basic site of the gel, it is likely that the protein is less
phosphorylated in the p110γ knockdown cell line when
compared to the control cells.
Phosphorylation of eukaryotic Elongation factor 2 (eEF2)
in response to IGF-I is PI3Kγ-dependent
To confirm the involvement of the regulation of eEF2
downstream of PI3Kγ, control and PI3Kγ knock-down
cells were stimulated with IGF-I and the lysates were
immunoblotted with anti-phospho-eEF2, followed by
stripping and reprobing of the western-blot with anti-
eEF2 antibody. The results demonstrated that the phos-
phorylation of eEF2 was decreased in p110γ knockdown
cells compared to that in the control cells, whereas theTable 2 List of differentially-expressed proteins between con
stimulation determined by DIGE and identified by MSa























a All other differentially-regulated spots were identified as BSA or keratin.total eEF2 protein was not affected (Figure 4C and densi-
tometry analysis 4D). Although the phosphorylation of
eEF2 was initially shown to be significantly different after
5 min of stimulation, the response seems to be more re-
producible and robust after 10 min of stimulation.
In addition, the lysates from parental MDA-MB-231
cells pre-treated with the isoform specific inhibitor,
AS605240, followed by stimulation with IGF-I were
immunoblotted with phospho-eEF2 and total eEF2 anti-
bodies. The results of these experiments showed that the
level of phospho-eEF2 in response to IGF-I was signifi-
cantly decreased after AS605240 treatment compared
with control cells (Figure 4E and densitometry analysis
4F). Taken together, these data indicate that eEF2 is
phosphorylated downstream of activation of the IGF-1R-
CXCR4 heterodimer in response to IGF-I and that this
is dependent on PI3Kγ activation.
Discussion
Activation of receptor tyrosine kinases (RTKs) and G-
protein coupled receptors GPCRs by their ligands leads
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Figure 4 Phosphorylation of eEF2 in response to IGF-I is PI3Kγ-dependent in MDA-MB-231 cells. (A) Spot map and three-dimensional
view of differentially expressed proteins, the spot circled with pink line represents spot 101. (B). Graph view of spot 101. (C) Control or p110γ
knockdown MDA-MB-231 cells were incubated in serum-free media for 1 hour before being stimulated with 0.1 nM IGF-I. Cell lysates were
prepared and subjected to SDS-PAGE and Western blot to detect phosphorylated eEF2. Membranes were stripped and reprobed for eEF2 and
β-actin as loading controls. These data are representative of at least 3 independent experiments conducted with similar results. (D) eEF2
phosphorylation was quantified by densitometry and normalized to the level of β-actin and expressed as a value relative to the 10 minute
control-treated values (mean ± SEM of three independent experiments). * - significantly different from control values (2-way ANOVA with
Bonferroni post-test) at *, p<0.05. (E) MDA-MB-231 cells were either untreated or treated with 2μM AS605240 and incubated in serum-free
media for 1 hour and stimulated with 0.1 nM IGF-I. Cell lysates were prepared and subjected to SDS-PAGE and Western blot to detect
phosphorylated eEF2. These data are representative of at least 3 independent experiments conducted with similar results. (F) eEF2 phosphorylation
was quantified by densitometry, normalized to β-actin and expressed as a value relative to the 10 minute control-treated values (mean ± SEM of
three independent experiments). * - significantly different from the control values (2-way ANOVA with Bonferroni post-test) at *, p<0.05.
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recent data indicate an important role for RTK-GPCR
transactivation in a number of physiological and patho-
logical cellular responses. This form of receptor transactiva-
tion has been shown to regulate cell proliferation [22-24],
migration and invasion [1,25,26] in various types of can-
cer, and our recent data indicate an important role for
IGF-1R and CXCR4 transactivation in migration of
MDA-MB-231 breast cancer cells [2]. This IGF-1R-
CXCR4 heterodimer appears to be linked with the metastatic
phenotype of these cells as the related but non-metastaticMCF-7 breast cancer cell line does not express functional
heterodimers. Therefore, it is important to understand how
IGF-1R-CXCR4 transactivation facilitates migration of
MDA-MB-231 cells. In the present study, three novel
observations with respect to IGF1-R and CXCR4 transacti-
vation were made. First, PI3Kγ is the major PI3K isoform
involved in IGF-I-induced cell migration of the metastatic
breast cancer cell line MDA-MB-231. Second, eEF2 is one
of the downstream targets of PI3Kγ after this heterodi-
meric receptor transactivation. Third, IGF-1R-CXCR4
transactivation leads to PI3Kγ-dependent phosphorylation
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breast cancer cell migration through a novel mechanism
by deactivating eEF2 after IGF-1R-CXCR4 transactivation.
Activation of the class IA PI3Ks, PI3Kα, β and δ fol-
lowing ligation of IGF-1R by IGF-1 is well documented
[27-30]. However, the two major PI3K isoforms known
to be activated downstream of GPCRs and to play a role
in cell migration in response to GPCR ligands are p110γ
and p110δ [4,9,31-33]. Thus, we investigated the expres-
sion of these PI3K isoforms in metastatic MDA-MB-231
and observed that these cells express both p110γ and
p110δ. Our previous data indicate that MDA-MB-231
cells express a functional IGF-R-CXCR4 heterodimer
whereas MCF-7 cells do not [2]. In fact, IGF-I signals
directly through IGF-1R in MCF-7 cells to control mi-
gration of the cells, independently of CXCR4 [2]. We
therefore investigated the level of expression of these
PI3K subunits in MCF-7 cells and found that while both
MCF-7 and MDA-MB-231 cells express similar levels of
p110δ, MCF-7 cells express a low level of p110γ.
PI3Kγ is generally activated by GPCRs, including che-
mokine receptors, such as CXCR4 [4], but to the best of
our knowledge, has not been implicated in IGF-1R sig-
naling. Here, we show that IGF-I stimulation leads to
the membrane translocation of p110γ, an indicator of
PI3K activation. Moreover, specific inhibition of PI3Kγ
and knockdown of p110γ resulted in decreased phos-
phorylation of Akt and cell migration in response to
IGF-I, whereas PI3Kδ did not appear to be involved in
this response. Taken together, these data indicate that
PI3Kγ is a major PI3K isoform regulating MDA-MB-231
breast cancer cell migration in response to IGF-I.
To shed light on the signaling pathways regulated by
p110γ downstream of IGF-1R-CXCR4 transactivation, we
performed a 2D DIGE proteomics experiment. We com-
pared the cytosolic proteome from MBA-MB-231 control
cells with MBA-MB-231 cells in which p110γ has been
knocked down after 5 min of IGF-I stimulation. Import-
antly, this short stimulation time allowed us to focus on
post-translational modifications to the MDA-MB-231 cell
proteome as this time point was too short for effects on
gene expression. These experiments identified eEF2 as one
of the downstream effectors of PI3Kγ after receptor
transactivation. eEF2 is known to play a critical role in
regulating protein synthesis by mediating the ribosomal
translocation from the A to the P-site in eukaryotic tissues,
the reaction that induces movement of mRNA along the
ribosome during translation [34]. Phosphorylation of eEF2
prevents functional binding to the ribosome and delays
the elongation step, thereby terminating translation [35].
PI3Ks have previously been implicated in the regulation of
the eEF2 downstream of proliferative signals [21], however
whether specific PI3K isoforms or all PI3K isoforms regu-
late eEF2 signaling has not yet been determined.Regulation of the eEF2 activity by PI3Kγ may be the
result of multiple molecular mechanisms. Firstly, PI3Kγ
may activate the eEF2 kinase through the mTOR/
P70S6K pathway, which has been shown as a key path-
way regulating eEF2 activity [21]. Secondly, PI3Kγ may
reduce the rate of eEF2 dephosphorylation through inhi-
biting the activity of a protein phosphatase such as pro-
tein phosphatase 2A (PP2A) [36,37]. The first protein
kinase substrate of PI3Kγhas been identified recently.
PI3Kγphosphorylates SET, an endogenous inhibitor of
PP2A, on two serine residues. eEF2 might therefore be a
direct or indirect substrate of PI3Kγ.
Cells can respond to growth factors by either migrat-
ing or proliferating, but not both at the same time, a
phenomenon termed “migration-proliferation dichot-
omy” [38], This is not only observed in cancer progres-
sion but also during wound healing and developmentand
the underlying mechanism remains unknown.. The pro-
posed physiological basis for this phenomenon is that
directional cell migration occurs along an increasing lig-
and gradient until migrating cells reach a zone in which
they start dividing as a result of the presence of ligands
that regulate proliferation. Thus limited protein synthe-
sis occurs in migrating cells, which diverts energy to the
process of migration. However, when cells stop migrat-
ing and start proliferating, protein synthesis is necessar-
ily upregulated. Our results support the view that
reduced proliferation is an integral part of migration
and, more specifically, that in metastatic breast cancer
cells the initiation of both processes might be regulated
by PI3Kγ.
It should be noted that the data presented in this
manuscript have been obtained using one breast cancer
cell line and further experimentation will be required to
determine the generality of our observation. This would
include examining different cell lines (from breast and
other cancers) and ideally, in cells from clinical tissue
samples. With respect to the latter, unfortunately at
present there is no means by which to identify cells in
tissues in which IGF1R/CXCR4 transactivation occurs.
However, ultimately, an improved understanding of the
molecular mechanisms underlying IGF1R/CXCR4 trans-
activation, including the role of PI3K signal transduction
pathways, in the progression of breast cancer metastasis
and invasion may lead to development of more effective
diagnostic and therapeutic strategies.
We have also observed that phosphorylation of eEF2
occurs upon stimulation of MDA-MB-231 cells with
CXCL12 (the chemokine ligand of CXCR4) in a PI3Kγ-
dependent manner (data not shown). Future studies
could determine if phosphorylation of eEF2 generally
occurs downstream of activated G-protein coupled
receptors. Importantly, the results of a recent study im-
plicate phosphorylation of eEF2 as an important link
Niu et al. Proteome Science 2013, 11:4 Page 9 of 12
http://www.proteomesci.com/content/11/1/4between the DNA damage response and translation of
mRNAs [16]. After activation of the DNA damage check-
point, AMPK mediates activation of eEF2 kinase, which in
turn phosphorylates eEF2. The authors conclude that be-
cause protein synthesis is energetically costly, stressed
cells inhibit this process to devote resources to the stress
response. That study, together with the observations in
the present study, implies that phosphorylation of
eEF2 to inhibit translation may be a general mechan-
ism regulating energy consumption between important
energy-dependent cellular processes.
Conclusion
In summary, we provide novel mechanistic data further
characterizing the downstream signalling pathways eli-
cited upon activation of the IGF-1R-CXCR4 heterodimer
in metastatic MDA-MB-231 breast cancer cells. Our
findings indicate that PI3Kγ may promote breast cancer
metastasis through a novel mechanism, by deactivating
eEF2 after IGF-1R-CXCR4 transactivation.
Methods
Cell lines and treatment conditions
Human breast cancer cell lines, the non-metastatic
MCF-7 and highly metastatic MDA-MB-231 cells, were
obtained from American Type Culture Collection
(ATCC; Manassas, VA, USA) [2,3]. The MDA-MB-231
p110γ knockdown cells were generated by lentiviral
transductions using shRNA constructs in pLKO.1 (Open
Biosystems Inc, Huntsville, USA) according to the man-
ufacturer’s instructions. The knockdown of p110γ was
confirmed by Western-blot analysis [17]. MCF-7 cells
were cultured in Dulbecco’s modified Eagle’s medium
(Gibco, USA) supplemented with 10% fetal bovine serum
whereas MDA-MB-231 cells were cultured in RPMI-
1640 (Gibco, USA) with 10% fetal bovine serum. For
IGF-I or inhibitor treatment, cells were incubated in
serum-free medium supplemented with 0.5% BSA
(Sigma-Aldrich, St Louis, MO, USA) for 1 hour.
Reagents
IGF-I was obtained from GroPep Pty Ltd (Adelaide, SA, Aus-
tralia). AS605240 was from Echelon Biosciences Inc (Salt
Lake City, UT, USA). IC87114 was from Australian Centre
for Blood Diseases (Monash University, Australia). Anti-
human Phosphoinositide 3-kinase γ, anti-phosphorylated-Akt
(S473), anti-Phospho-eEF2 (Thr56) and anti-eEF2 antibodies
were purchased from Cell Signaling Technology (Danvers,
MA, USA). Anti-pan-cadherin and anti-β-actin antibodies
were obtained from Sigma-Aldrich (St Louis, MO, USA).
Rabbit anti-p110δ antibodies were produced from peptides
using standard immunization. The immunizing peptide was
KVNWLAHNVSKDNRQ.Membrane fractionation
The cells were washed, scraped, and suspended in hypo-
tonic buffer (10 mM Tris–HCl (pH 7.9) containing 1.5
mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, 0.1%
Nonidet P-40, and protease inhibitors); incubated on ice
for 10 min; homogenized with 20 strokes of a glass
Dounce homogenizer; and centrifuged at 500 × g for 5
min at 4°C to yield the nuclear fraction. The nuclear
fraction was then suspended in 200 μl of extraction buf-
fer (20 mM Tris–HCl (pH 7.9) containing 20% glycerol,
1.5 mM MgCl2, 0.5 mM dithiothreitol, and protease
inhibitors), and 4 M KCl was added to a final concentra-
tion of 0.3 M. The final suspension was rocked for 30
min at 4°C and centrifuged at 13,000 × g for 15 min to
yield the nuclear fraction. The 500 × g post-nuclear
supernatant fraction was further fractionated by centrifu-
gation at 100,000 × g for 1 h at 4°C. The resulting pellet
was dissolved in 5-fold Laemmli buffer and designated as
the membrane fraction.Immunoprecipitation and western blot analysis
Cells were lysed in lysis buffer (50 mM Tris [pH 7.5], 1%
[wt/vol] NP-40, 150 mM NaCl, 1 mM ethylene diamine tet-
raacetic acid (EDTA), 1.5 mM MgCl2, 50 mM NaF, 1 mM
Na3VO4, 1 mM phenylmethylsulfonyl fluoride) and 1% pro-
tease inhibitors (Sigma, USA) on ice for 30 min. The lysates
were centrifuged at 13,000 × g for 10 min at 4°C. The super-
natant was collected and the protein concentration was
determined using the BCA protein assay (Pierce). For
immunoprecipitation, the lysates (1 mg of total protein)
were incubated with 1 μg of anti-p110γ, at 4°C overnight.
Immunocomplexes were precipitated with protein A-
sepharose beads at 4°C for 1 h. After three washes with lysis
buffer, the bound proteins were eluted from the column in
preheated sample buffer (50 mM Tris–HCl pH 6.8, 50 mM
dithiothreitol, 1% SDS, 0.005% bromphenol blue, and 10%
glycerol). For whole lysate sample preparation, the lysates
(50 μg of total proteins/well) were denatured by boiling for
5 min in sample buffer. The immunoprecipitates and whole
lysates were then subjected to 10% SDS-PAGE, transferred
to PVDF membrane (Millipore, USA), and analyzed by
Western blotting.The transferred membranes were blocked
with 5% skim milk powder and incubated with primary
Abs (1:1000 of anti-phosphorylated-Akt (S473), 1:1000 of
anti-Phospho-eEF2, 1:1000 of anti-eEF2, 1:1000 of anti-pan
cadherin, 1:500 of anti-p110γ, 1:5000 of anti-β-actin) over-
night at 4°C followed by horseradish peroxidase-conjugated
goat anti-rabbit IgG (1:50000) or horseradish peroxidase-
conjugated goat anti-mouse IgG (1:1000). Membranes were
visualized by enhanced chemiluminescence (Sigma, USA).
Membranes were stripped with RestoreTM Western Blot
Stripping Buffer (Pierce, Rockford) according to the
manufacturer’s instructions.
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Chemotaxis was measured in a modified Boyden Cham-
ber as described previously [2].
Preparation of protein samples and 2D-DIGE
Control and p110γ knockdown MDA-MB-231 cells ei-
ther unstimulated or stimulated with IGF-I for 5 min-
utes were lysed in hypotonic lysis buffer (10 mM Hepes,
pH 7.9, 133 mM sorbitol, containing 5 mM NaF, 2 mM
Na3VO4, 1 mM PMSF and protease inhibitor (1:100,
Sigma-Aldrich) for 10 min at 4°C, homogenized, and
then spun at 800 × g for 10 min. The pellet was washed
with the hypotonic buffer and the supernatants were
combined to generate the cytosolic fraction. These sam-
ples were then precipitated with a Clean-up kit (GE
Healthcare, UK) and suspended in labeling buffer (7 M
Urea, 2 M Thiourea, 4% (w/v) CHAPS, 30 mM Tris, pH
8.5). Protein concentrations in the control and PI3Kγ
knockdown cell lines were determined by an EZQ pro-
tein quantitation assay (Invitrogen/Molecular Probes)
against an ovalbumin standard curve according to the
manufacturer’s instructions. Each of the tested condi-
tions (resting and IGF-I-stimulation) was repeated in
triplicate. Protein from each sample was labeled accord-
ing to the manufacturer’s instructions (GE Health care)
with CyDyes (Cy2, Cy3 and Cy5). Briefly, 50 μg of pro-
tein from each sample were labeled with 200 pmol of ei-
ther Cy3 or Cy5 and a reverse-labeling approach was
used to avoid dye-labeling bias. The gel-to-gel variation
was excluded by using an internal protein standard (IPS)
sample, obtained by mixing equal amounts of proteins
from the test conditions. As common practice, the Cy2
minimal dye (GE Healthcare) was used to label the IPS
prepared by pooling 25 μg of protein from each sample
(150 μg of total protein).
Six individual samples from the control and p110γ
knockdown cells under each of the test conditions (con-
trol and IGF-I-stimulation) were co-resolved in 6 differ-
ent 2D-DIGE gels. Isoelectric focusing (IEF) was
performed on an immobilized non-linear pH 3–11 gradi-
ent of 24 cm length (GE Healthcare), using an Ettan
IPGphor II system (GE Healthcare) with the current lim-
ited to 50 μA per strip. Following IEF, the strips were
equilibrated in equilibration buffer (Gel Company) with
6 M urea added, containing 10 mg/ml of DTT for 15
minutes followed by the exchange of solution for equili-
bration buffer that contained 25 mg/ml of iodoacetamide
(IAA) in place of DTT. SDS-PAGE in the second dimen-
sion was carried out using 12.5% 2D gel DALT NF pre-
cast polyacrylamide gels (Gel Company). Electrophoretic
separation was performed using an Ettan Dalt 12 Separ-
ation Unit (GE Healthcare) in the electrophoresis buffer
provided with the pre-cast gels at 25°C using the follow-
ing conditions: 50 V, 5 mA/gel, 0.5 W/gel, for 1 hour,110 V, 10 mA/gel, 0.5 W/gel, for 1 hour, 250 V, 30 mA/
gel, 2.5 W/gel until the dye-front emerged from the bot-
tom of the gel. Gel images of Cy2, Cy3, and Cy5 were
scanned by using Typhoon Trio at 100 μm resolution
(GE Healthcare). To assure that the image was not satu-
rated, the PMT voltage (550 V) was altered, that the
pixel intensities in the scanned image was below 80,000
counts.
Spot detection, quantification and comparisions
Image analysis was undertaken using DeCyder 2D soft-
ware (version 7, GE Healthcare). The control and p110γ
knockdown samples were compared using a two-tailed
Students t-test to detect spots that were differentially
expressed. Those spots that returned a p-value of <0.05
were accepted and selected for protein in-gel digest, LC-
eSI-I MS/MS analysis, and identification.
LC-ESI-MS/MS
Protein spots showing statistically significant differences
in expression between control and p110γ knockdown
cells were excised from the gel using an Ettan Spot
Picker (GE Healthcare), reduced, alkylated and digested
using trypsin (100 ng of sequencing grade modified tryp-
sin (Promega) in 5 mM ammonium bicarbonate in 10%
Acetonitrile (ACN)). After extraction with 1% formic
acid (FA) in water, 1% FA in 50% ACN and 100% ACN,
the volumes of the resulting peptide extracts were
reduced by vacuum centrifugation to approximately 1
μL. Vacuum concentrated samples were resuspended
with 0.1% FA in 2% ACN to total volume of ~8 μL. LC-
ESI-IT MS/MS was performed using an online 1100
series HPLC sytem (Agilent Technologies) and HCT
Ultra 3D-Ion-Trap mass spectrometer (Bruker Dal-
tonics). The LC system was interfaced to the MS using
an Agilent Technologies Chip Cube operating with a
ProID-Chip-150 (II), which integrates the enrichment
column (Zorbax 300SB-C18, 4mm, 40 nL), analytical
colum (Zorbax 300 SB-C18, 150 mm × 75 μm), and
nanospray emitter. Five microlitres of sample was loaded
on the enrichment column at the flow rate of 4 μL/min
in mobile phase A (0.1% FA in 98% m/v ACN) over 32
min at 300nL/min. Ionizable species (300< m/z <1,200)
were trapped and the most intense ions eluting at the
time were fragmented by collision-induced dissociation.
Active exclusion was used to exclude a precursor ion for
30 seconds following the acquisition of two spectra.
MS and MS/MS spectra were subjected to peak detec-
tion and de-convolution using DataAnalysis (Version 3.4,
Bruker Daltonics, Billerica, MA, USA). Compound lists
were exported to mascot generic format (mgf ) and
submitted to theMASCOT database-searching engine
(Version 2.2, Matrix Science, Boston, MA, USA). The
search parameters were as follows: Swissprot release 57.7,
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sin (2 missed cleavages), Fixed modifications: Carbami-
domethyl (C), Variable modifications: Oxidation (M),
N-terminal Glutamine to pyro-glutamic acid, N-terminal
Glutamic acid to pyro-Glutamic acid; Mass tolerances MS
0.3 Da, MS/MS: 0.4 Da. Protein identifications were made
on the basis of having at least two matching unique pep-
tides with individual ion scores above the mascot 0.05 sig-
nificance threshold (95% confidence).
Quantitation of western blot densitometry
Gelbands were quantified usingImagequantsoftware (GE
Healthcare, USA). All values were normalized to the ap-
propriate loading control (β–actin) and then expressed as
a value relative to the 10 minute control-treated values es-
sentially as previously described [39].
Statistical analysis
Statistical analyses were conducted by unpaired Stu-
dent’s t-tests analysis or 2-way ANOVA with Bonferroni
post-tests, as stated in the figure legends, using Graph-
Pad Prism software (GraphPad Software, Inc, USA).
Design of the study
The experimental design is outlined in Additional file 1:
Figure S1.
Additional file
Additional file 1: Figure S1. Work flow used in this study.
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